IL296835A - Process for preparing parp inhibitor, crystalline forms, and uses thereof - Google Patents

Process for preparing parp inhibitor, crystalline forms, and uses thereof

Info

Publication number
IL296835A
IL296835A IL296835A IL29683522A IL296835A IL 296835 A IL296835 A IL 296835A IL 296835 A IL296835 A IL 296835A IL 29683522 A IL29683522 A IL 29683522A IL 296835 A IL296835 A IL 296835A
Authority
IL
Israel
Prior art keywords
compound
crystalline form
hydrate
sesqui
crystalline
Prior art date
Application number
IL296835A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58099633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL296835(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IL296835A publication Critical patent/IL296835A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
IL296835A 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof IL296835A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015088003 2015-08-25
PCT/CN2016/096200 WO2017032289A1 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Publications (1)

Publication Number Publication Date
IL296835A true IL296835A (en) 2022-11-01

Family

ID=58099633

Family Applications (2)

Application Number Title Priority Date Filing Date
IL296835A IL296835A (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof
IL257442A IL257442B2 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL257442A IL257442B2 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms and their uses

Country Status (15)

Country Link
US (1) US10457680B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341375B1 (cg-RX-API-DMAC7.html)
JP (1) JP6940039B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180041748A (cg-RX-API-DMAC7.html)
CN (2) CN112521390A (cg-RX-API-DMAC7.html)
AU (1) AU2016312011B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003634B1 (cg-RX-API-DMAC7.html)
CA (1) CA2994895A1 (cg-RX-API-DMAC7.html)
EA (1) EA037366B1 (cg-RX-API-DMAC7.html)
IL (2) IL296835A (cg-RX-API-DMAC7.html)
MX (1) MX385450B (cg-RX-API-DMAC7.html)
NZ (1) NZ739876A (cg-RX-API-DMAC7.html)
TW (1) TWI736550B (cg-RX-API-DMAC7.html)
WO (1) WO2017032289A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201800765B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171883T1 (hr) 2011-12-31 2018-01-12 BeiGene, Ltd., Mourant Ozannes, Corporate Services (Cayman) Limited Kondenzirani tetra ili penta-ciklički dihidrodiazepinokarbazoloni kao parp inhibitori
IL296835A (en) 2015-08-25 2022-11-01 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
WO2019015561A1 (en) * 2017-07-17 2019-01-24 Beigene, Ltd. TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY
MX2020012259A (es) 2018-05-18 2021-01-29 Novartis Ag Formas cristalinas de un inhibidor de tlr7/tlr8.
AU2019275722A1 (en) * 2018-06-01 2020-11-12 Beigene, Ltd. Maintenance therapy of a PARP inhibitor in treating gastric cancer
USD926356S1 (en) * 2019-03-14 2021-07-27 Tuanfang Liu Battery for electronic cigarette
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法
CN113402502B (zh) * 2019-05-16 2022-10-14 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体制备的物料组合体系
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
JP2022534093A (ja) * 2019-05-31 2022-07-27 ベイジーン リミテッド Ｐａｒｐ阻害剤ペレット製剤及びその調製方法
CN112007011B (zh) * 2019-05-31 2024-07-23 百济神州(苏州)生物科技有限公司 一种parp抑制剂微丸胶囊及其制备工艺
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2218110T3 (es) 1999-01-11 2004-11-16 Agouron Pharmaceuticals, Inc. Inhibidores triciclicos de poli(adp-ribosa)polimerasas.
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
KR100697746B1 (ko) * 2003-01-09 2007-03-22 화이자 인코포레이티드 키나제 저해제로서의 디아제피노인돌 유도체
PT2767537T (pt) 2008-08-06 2017-07-17 Medivation Technologies Inc Inibidores de di-hidropiridoftalazinona de poli(adp-ribose)polimerase (parp)
HRP20171883T1 (hr) 2011-12-31 2018-01-12 BeiGene, Ltd., Mourant Ozannes, Corporate Services (Cayman) Limited Kondenzirani tetra ili penta-ciklički dihidrodiazepinokarbazoloni kao parp inhibitori
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
IL296835A (en) 2015-08-25 2022-11-01 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
WO2019015561A1 (en) 2017-07-17 2019-01-24 Beigene, Ltd. TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法

Also Published As

Publication number Publication date
CA2994895A1 (en) 2017-03-02
EP3341375A1 (en) 2018-07-04
MX385450B (es) 2025-03-18
CN107922425B (zh) 2021-06-01
WO2017032289A1 (en) 2017-03-02
EP3341375A4 (en) 2019-01-16
TWI736550B (zh) 2021-08-21
EA201890547A1 (ru) 2018-07-31
EP3341375B1 (en) 2022-04-13
CN107922425A (zh) 2018-04-17
AU2016312011B2 (en) 2021-02-04
TW201718586A (zh) 2017-06-01
IL257442B (en) 2022-11-01
KR20180041748A (ko) 2018-04-24
ZA201800765B (en) 2019-10-30
US20190177325A1 (en) 2019-06-13
MX2018002322A (es) 2018-04-11
BR112018003634A2 (en) 2018-11-21
BR112018003634A8 (pt) 2023-01-17
CN112521390A (zh) 2021-03-19
NZ739876A (en) 2022-09-30
EA037366B1 (ru) 2021-03-18
IL257442A (en) 2018-04-30
AU2016312011A1 (en) 2018-03-08
JP6940039B2 (ja) 2021-09-22
IL257442B2 (en) 2023-03-01
US10457680B2 (en) 2019-10-29
JP2018528199A (ja) 2018-09-27
BR112018003634B1 (pt) 2023-11-21

Similar Documents

Publication Publication Date Title
IL296835A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
US20230049952A1 (en) Methods and compounds for restoring mutant p53 function
CN113874019A (zh) 用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
NZ735715A (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
IL282988B1 (en) Methods of treating cystic fibrosis
IL290338B1 (en) Solid dispersions containing sgc activator
JP2018500377A (ja) 癌の治療を目的とする、ユビキチン特異的プロテアーゼ７（ｕｓｐ７）阻害剤としてのピロロトリアジノン誘導体及びイミダゾトリアジノン誘導体
JP7636646B2 (ja) Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
EP3612527B1 (en) Heterocyclic compounds useful as modulators of acetylcholine receptors
IL269347B (en) Ip6k inhibitors
IL271910B2 (en) Pyrrolopyrimidine and pyrrolopyridine derivatives inhibit ask1
IL303962A (en) The tricyclic compound
IL265523A (en) A method of treating cancer through a combination of harmful substances and pk-DNA inhibitors
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
CN115433187A (zh) 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
JPWO2016171142A1 (ja) 複素環化合物
CN119173510A (zh) 一种羟基酰胺类衍生物及其应用
WO2021143922A1 (zh) 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法
HK40040143A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
TW202519531A (zh) 含丙烯酮類生物抑制劑的晶型及其製備方法和應用
HK40063773A (en) Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases